Sanofi Fined $52.8 Million for Denigrating Plavix Copies
This article is for subscribers only.
Sanofi, France’s largest drugmaker, was fined 40.6 million euros ($52.8 million) by the country’s competition regulator for trying to limit sales of generic versions of the company’s Plavix blood thinner.
Sanofi denigrated the copies of the drug to doctors and pharmacists, the regulator said in a statement on its website today. The Competition Authority was acting on a complaint by Teva Pharmaceutical Industries Ltd., the world’s biggest maker of generic medicines.